This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML

This study has been completed.
Information provided by:
University Hospital Muenster Identifier:
First received: September 6, 2006
Last updated: August 18, 2009
Last verified: August 2009
The primary purpose of the study is to determine, whether the addition of Sorafenib to standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results (event free survival).

Condition Intervention Phase
Acute Myeloid Leukemia Drug: Sorafenib Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled, Randomized, Multi-center Phase II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML

Resource links provided by NLM:

Further study details as provided by University Hospital Muenster:

Primary Outcome Measures:
  • Median Event Free Survival of all AML patients

Secondary Outcome Measures:
  • Median Event Free Survival of AML patients with Flt3-ITD mutations
  • Median Event Free Survival of the patients in each of the four strata (Flt3 Non-ITD/NPM1 WT, Flt3 Non-ITD/NPM1 mut, Flt3 ITD/NPM1 WT, Flt3 ITD/NPM1 mut)
  • Median Overall Survival of AML patients with Flt3-ITD mutations
  • Median Overall Survival of all AML patients
  • Rate of Complete Remission in all AML patients
  • Rate of Molecular Remission in all AML patients
  • Toxicity
  • Evidence of Minimal Residual Disease in all AML patients
  • Development of Biomarkers indicating the course of disease

Estimated Enrollment: 200
Study Start Date: September 2006
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: A
Chemotherapy + Placebo
Drug: Placebo
Chemotherapy + Placebo
Active Comparator: B
Chemotherapy + Sorafenib
Drug: Sorafenib
2 x 400 mg/d
Other Name: Nexavar


Ages Eligible for Study:   61 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with newly diagnosed AML (except APL) according to the FAB and WHO classification, including AML evolving from MDS or other hematologic diseases and AML after previous cytotoxic therapy or radiation (secondary AML)
  • Bone marrow aspirate or biopsy must contain >= 20% blasts of all nucleated cells, with the exception of AML FAB M6, where >= 30% of non-erythroid cells must be leukemic blasts
  • Age >= 61 years
  • Informed consent, personally signed and dated to participate in the study
  • Male patients enrolled in this trial must use adequate barrier birth control measures during the course of the Sorafenib treatment and for at least 3 months after the last administration of Sorafenib

Exclusion Criteria:

  • Central nervous system manifestation of AML
  • Cardiac Disease: Heart failure NYHA III° or IV°; active coronary artery disease (MI more than 6 months prior to study entry is permitted); serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)
  • Chronically impaired renal function (creatinin clearance < 30 ml/min)
  • Chronic pulmonary disease with relevant hypoxia
  • Inadequate liver function (ALT and AST >= 2.5 x ULN)
  • Total bilirubin >= 1.5 x ULN
  • Resting blood pressure (BP) consistently higher than systolic 160 mmHg and/or diastolic 95 mmHg
  • Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardise compliance with the protocol
  • Uncontrolled active infection
  • Concurrent malignancies other than AML
  • Previous treatment of AML except hydroxyurea and up to 2 days <= 100 mg/m²/d cytarabine
  • Known HIV and/or hepatitis C infection
  • Evidence or history of CNS disease, including primary or metastatic brain tumors, seizure disorders
  • Thrombotic or embolic events such as cerebrovascular accident or pulmonary embolism within 1 year of study entry
  • Evidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy
  • History of organ allograft
  • Concomitant treatment with kinase inhibitors, angiogenesis inhibitors and Myelotarg
  • Patients with major surgery, open biopsy or significant traumatic injury within 4 weeks of start or first dose
  • Serious, non-healing wound, ulcer or bone fracture
  • Allergy to study medication or excipients in study medication
  • Investigational drug therapy outside of this trial during or within 4 weeks of study entry
  • Patients who are not eligible for standard chemotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00373373

Charité Campus Benjamin Franklin, Med. Klinik III
Berlin, Germany, 12203
Klinikum Chemnitz GmbH, Klinik für Innere Medizin III
Chemnitz, Germany, 09113
Universitätsklinikum Carl Gustav Carus der TU Dresden, Medizinische Klinik I
Dresden, Germany, 01307
St. Johannes Hospital, Medizinische Klinik II
Duisburg, Germany, 47166
Universitätsklinikum Essen, Zentrum für Innere Medizin, Medizinische Klinik und Poliklinik für Hämatologie
Essen, Germany, 45147
Klinikum der J. W. Goethe-Universität Frankfurt am Main, Medizinische Klinik II
Frankfurt / Main, Germany, 60590
Allgemeines Krankenhaus St. Georg, Hämatologische Abteilung
Hamburg, Germany, 20099
Universitätsklinikum Heidelberg, Med. Klinik V
Heidelberg, Germany, D-69120
Klinikum der Universität zu Köln, Klinik I für Innere Medizin
Köln, Germany, 50937
Klinikum der Johannes Gutenberg Universität, 3. Medizinische Klinik und Poliklinik
Mainz, Germany, 55101
Philipps Universität, Abteilung für Hämatologie, Onkologie und Immunologie
Marburg, Germany, 35043
Klinik für Hämatologie und Onkologie Klinikum Minden
Minden, Germany, 32423
TU München, Medizinische Klinik III
München, Germany, 81675
Universitätsklinikum Münster, Medizinische Klinik A
Münster, Germany, 48149
Klinikum Nürnberg, 5. Medizinische Klinik Einheit für Knochenmarktransplantation
Nürnberg, Germany, 90419
Universität Regensburg, Abteilung für Hämatologie und Internistische Onkologie
Regensburg, Germany, 93042
Robert-Bosch Krankenhaus Stuttgart
Stuttgart, Germany, 70376
Julius-Maximilians-Universität Würzburg, Medizinische Klinik und Poliklinik II
Würzburg, Germany, 97979
Sponsors and Collaborators
University Hospital Muenster
Principal Investigator: Hubert Serve, MD Klinikum der J.W. Goethe Universität Frankfurt, Med. Klinik II
  More Information

Responsible Party: Hubert Serve (Principal Investigator), Klinikum der J.W. Goethe Universität Frankfurt, Med. Klinik II Identifier: NCT00373373     History of Changes
Other Study ID Numbers: KKS/INNERE_A/AML2006
EudraCT Number: 2005-005966-35
Sorafenib in AML
Study First Received: September 6, 2006
Last Updated: August 18, 2009

Keywords provided by University Hospital Muenster:
Acute Myeloid Leukemia
Kinase Inhibitor

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs processed this record on August 18, 2017